Curcumin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
103 randomised trials across 42 outcomes, with high-certainty evidence for four of them, including CRP. Absorption is the whole problem, so the evidence belongs to specific formulations rather than to turmeric.
- People given it
- 195
- Human studies
- 3
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
Sold as a dietary supplement, and turmeric is generally recognised as safe as a food. Not approved to treat any condition.
5 effects reported, 3 unwanted, 2 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Curcumin is the yellow stuff in turmeric. People take pills of it for pain and swelling. The spice in food is not the same as the pill. The pills use special forms because plain curcumin barely gets into the blood. It is a supplement, not a drug.
What people take it for
- Less joint pain.
- Lower swelling numbers on a blood test.
- A longer life, because it is in a lot of ageing stacks.
What the trials actually showed
Mice first. The US ageing mouse programme tested curcumin. Those mice did not live longer. Now people. A 2024 review pooled 103 randomised trials in 7216 people. Only four of 42 outcomes had high certainty. Those four were fasting blood sugar, CRP, HDL and weight. Across 66 trials, CRP fell 0.58 mg/L. A 45 person rheumatoid arthritis pilot compared curcumin with a pain drug. A 50 person knee trial used a high absorption form and pain scores fell. A 100 person metabolic syndrome trial used curcumin with piperine and lipids moved. Nobody has shown that moving those numbers prevents a heart attack. Turmeric root is only 2 to 5 percent curcuminoids. Food is not a trial dose.
What people report
Reports, not trial results
The good
- Some people say their knees feel better after a few weeks of a trial style pill.
- Stomach upset is usually the only complaint at normal pill doses.
The bad
- A lot of people feel nothing and stop.
- Cheap turmeric capsules are not the form the trials used.
- Rare liver injury has been reported with high dose high absorption products.
Where these come from: The trial counts and marker changes are from the reviews and trials on this page. The no effect and stomach reports are from supplement forums. Those are not from a trial.
My bottom line
It can move a blood marker. It did not make mice live longer. I would not take it to live longer.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Curcumin has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Cholesterol and blood fats100 people · 1 study
- Joint and knee pain95 people · 2 studies
Measured in animals or cells, not yet in people
Real results that answer a different question from a trial. Where a human trial is missing on a compound nobody can patent, the reason is usually that no sponsor would ever recover the cost of running one. The record on this one is set out below.
- Living longer1 preclinical study
32 of the 36 indexed goals have no study of any kind behind Curcumin
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about Curcumin and one of these did not come from a study cited here.
When this earns a spot
It earns a spot when hs-CRP is up and you are well enough that the number is not just a cold. Formulation is the whole product. Powder is not phytosome. It does not earn a spot because JUPITER used CRP to pick statin patients.
Owner stack tier 2
Bloodwork that belongs beside the bottle
Repeat a high value before you buy the bottle.
Default retest window: 90 days. If the named marker did not move, stop.
- Do not baseline hs-CRP after a fever, a race, or dental work.
- Biotin can interfere with some immunoassays.
Reading the number
Under 1 mg/L is a lower-risk conversation band on many lab sheets. Over 10 is usually acute. If ninety days of the same formulation did not move a stable hs-CRP, stop.
Marker glossary: hs-CRP.
What people typically order
Ask for hs-CRP on a well day. The partners page is /bloodwork/partners. Quality of the bottle is /supplements/quality.
Show full evidence
Overview
103 randomised trials across 42 outcomes, with high-certainty evidence for four of them, including CRP. Absorption is the whole problem, so the evidence belongs to specific formulations rather than to turmeric.
Curcumin has one of the largest randomised literatures of any plant compound, and reading it requires separating three things that get conflated: turmeric the spice, curcumin the molecule, and the specific enhanced-absorption formulations that trials actually use.
A 2024 review pooled 103 randomised trials in 7,216 participants across 42 outcomes. Roughly 55% of outcomes were statistically significant, and the evidence was rated high certainty for exactly four: fasting blood sugar, C-reactive protein, HDL and weight. Everything else was moderate, low or very low. A separate GRADE-assessed analysis of 66 trials found CRP down 0.58 mg/L, TNF-alpha and IL-6 both reduced, and IL-1 beta unchanged.
So curcumin measurably lowers inflammatory markers. Whether lowering them changes how anyone's life goes is not what these trials measured.
Mechanism of action
Curcumin is a polyphenol that interacts with a very large number of molecular targets, which is both its appeal and a reason for caution, since promiscuous binding in vitro often does not translate. The best-supported actions are inhibition of NF-kappa-B signalling, which reduces transcription of inflammatory cytokines, and Nrf2 activation raising endogenous antioxidant enzyme expression. Its central pharmacological problem is bioavailability: plain curcumin is poorly absorbed, rapidly glucuronidated and sulfated in the intestine and liver, and cleared fast. Every commercial strategy, piperine co-administration, phytosome complexes, nanoparticle and micellar formulations, exists to solve that, and each produces different plasma exposure.
Human evidence
Large randomised base with consistent effects on inflammatory and metabolic markers. High-certainty evidence exists for four outcomes out of 42, and no trial has measured a hard clinical event.
- 103 randomised trials, 7,216 participants: high certainty for fasting blood sugar, CRP, HDL and weight. Everything else moderate or worse.
- 66 trials pooled for inflammation: CRP down 0.58 mg/L, TNF-alpha and IL-6 both down, IL-1 beta unchanged.
- The inconsistent findings cluster where absorption differs, which is what you would expect if formulation drives exposure and exposure drives effect.
- Osteoarthritis symptom trials are among the more positive clinical applications, with effect sizes modest and comparators often active rather than placebo. A 50 person Theracurmin trial reported lower knee pain VAS at 8 weeks.
- A 45 person rheumatoid arthritis pilot and a 100 person metabolic-syndrome lipid trial are the human papers this page now cites beside the reviews.
- Safety across this literature is good at supplement doses, with gastrointestinal complaints the usual adverse effect. Rare hepatotoxicity has been reported with high-dose enhanced-absorption products.
What this does not tell you: Two limits dominate. First, almost every endpoint is a biomarker. Lowering CRP by 0.58 mg/L is a measurable change in a number that predicts risk; no curcumin trial has shown that lowering it this way prevents anything. Second, the evidence attaches to formulations rather than to the molecule. A trial of a phytosome complex says little about a plain turmeric capsule, and nothing about turmeric in food, where curcuminoid content is only 2 to 5%. The 2024 review's own authors flag methodological quality across the included studies as a limitation.
Reading the research record
One thing this page must state before the rest: curcumin went through the National Institute on Aging's Interventions Testing Program, the only multi-site lifespan programme in genetically heterogeneous mice, and produced no significant lifespan effect in either sex. Anyone taking it as a longevity compound is acting against the one rigorous lifespan test that exists. The inflammatory marker evidence below is real and is a different claim.
Curcumin is also the cleanest example in this pillar of a compound whose evidence is real but attached to the wrong thing. A reader who sees 103 randomised trials reasonably concludes that curcumin is well studied, and it is. What the number hides is that only four of 42 outcomes reached high certainty, and that the trials used specific engineered formulations chosen to solve an absorption problem that a spice jar does not solve.
That matters practically. If you are taking curcumin because your CRP is up, the trials support a formulation with demonstrated absorption, at a trial dose, with a retest of CRP to tell you whether it worked for you. If you are taking turmeric powder in food for the same reason, you are doing something the literature has not tested.
The evidence, charted
Fig. 1a · evidence scale
195people, across 3 human studies cited here
- 2014 · Complementary Therapies in Medicine10051%
- 2014 · Journal of Orthopaedic Science5026%
- 2012 · Phytotherapy Research4523%
One study holds 51% of these participants, so the total is less independent than its size suggests. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 7 citations here are human work, the rest are not.
- Human · given to people343%
- Animal · given to animals114%
- Review · summarises other work343%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 2012 to 2024, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Supplement
- Molecular weight
- 368.4 Da. Turmeric root is roughly 2 to 5% curcuminoids, so the spice and the extract are not interchangeable doses.
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Very short for unformulated curcumin, with extensive first-pass conjugation and plasma concentrations often near the limit of detection after ordinary doses. Enhanced formulations report multi-fold increases in exposure, and those multiples are formulation-specific rather than a property of curcumin.
No amino acid sequence is on file for Curcumin, which is expected: a supplement is not built from residues.
Key studies & citations
- Review2024Curcumin on human health: a comprehensive systematic review and meta-analysis of 103 randomized controlled trials
103 randomised trials, 7,216 participants, 42 outcomes. 23 of 42 outcomes were statistically significant. Certainty was rated high for only four: fasting blood sugar, C-reactive protein, HDL and weight. Ten outcomes were moderate, 14 low and 14 very low. The authors note limitations in the methodological quality of the included studies.
- Review2023Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials
66 randomised trials. CRP down 0.58 mg/L (95% CI minus 0.74 to minus 0.41), TNF-alpha down 3.48 pg/mL and IL-6 down 1.31 pg/mL. IL-1 beta was unchanged at minus 0.46 pg/mL (95% CI minus 1.18 to 0.27). Antioxidant markers improved.
- Review2023Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis
The closest this literature comes to a clinical rather than biochemical endpoint, in a defined inflammatory disease. Included because it is a symptom and disease-activity analysis rather than a marker analysis.
- Human2012A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis
A very small rheumatoid arthritis pilot put 45 people on curcumin, a pain drug, or both. Disease activity scores fell in every arm, and the curcumin arm looked best. 45 people split three ways cannot settle a disease this long. Treat it as a reason to run a proper trial, not as proof.
45 adults with active rheumatoid arthritis randomised to curcumin 500 mg, diclofenac 50 mg, or both. DAS28 and ACR scores improved in all three arms, with the largest percentage improvement on curcumin alone. Pilot size.
- Human2014Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial
A high absorption curcumin plus piperine mix moved blood lipids in people who already had metabolic syndrome. 100 people took 1000 mg a day of the mix, or a dummy, for 8 weeks on top of usual care. LDL, triglycerides and total cholesterol fell, and HDL rose. This is a lipid trial of a specific formulation, not a turmeric-in-food result and not an event trial.
100 adults with metabolic syndrome randomised to curcuminoids 1000 mg/day plus piperine or placebo for 8 weeks, on standard care. LDL, non-HDL, total cholesterol, triglycerides and lipoprotein(a) fell versus placebo; HDL rose. Small dense LDL did not separate.
- Human2014Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study
A high absorption curcumin form eased knee pain in a short trial. 50 adults with knee osteoarthritis took 180 mg a day, or a dummy, for 8 weeks. Pain scores were lower on the curcumin form except in people who started with almost no pain. They also used less celecoxib. Eight weeks is short, and this is one formulation.
50 adults with Kellgren-Lawrence grade II or III knee osteoarthritis randomised to Theracurmin 180 mg/day curcumin or placebo for 8 weeks. Knee pain VAS was lower on Theracurmin except in those with baseline VAS of 0.15 or less. Celecoxib use was lower. No major side effects reported.
- Animal2013Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice
NIA Interventions Testing Program. Lifelong curcumin from 4 months of age did not extend lifespan in male or female genetically heterogeneous mice at the concentration tested.
Frequently asked questions
Has Curcumin been tested in people?
103 randomised trials across 42 outcomes, with high-certainty evidence for four of them, including CRP. Absorption is the whole problem, so the evidence belongs to specific formulations rather than to turmeric. 3 completed trials, 195 people given it. 195 people given it across 3 completed trials. 0 found nothing.
What is the Curcumin dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. Sold as a dietary supplement, and turmeric is generally recognised as safe as a food. Not approved to treat any condition.
Is Curcumin FDA-approved?
Sold as a dietary supplement, and turmeric is generally recognised as safe as a food. Not approved to treat any condition.
Is turmeric the same as curcumin?
No, and the difference is large enough to matter. Turmeric root is roughly 2 to 5% curcuminoids, and curcumin on its own absorbs poorly. Trials use enhanced-absorption formulations, with piperine, phytosome complexes or nanoparticles, precisely because plain curcumin barely reaches the bloodstream.
Does it actually reduce inflammation?
It reduces inflammatory markers, reliably. Across 66 randomised trials CRP fell by 0.58 mg/L, with TNF-alpha and IL-6 also down and IL-1 beta unchanged. Whether that change prevents any disease is a separate question no trial has answered.
Which formulation should I use?
One that a trial used. Because absorption is the limiting factor and each strategy produces different plasma exposure, evidence does not transfer freely between products. This is the case where matching the product to the study is not fussiness, it is the whole thing.
Is it safe?
At supplement doses, generally yes, with stomach upset the common complaint. Rare liver injury has been reported with high-dose enhanced-absorption products, which is a reminder that improving the absorption of a compound also improves the absorption of its risks.
Latest reading on Curcumin
Articles from the blog that cover Curcumin, newest first.